• +1-646-491-9876
    • +91-20-67278686

    Search

    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Pipeline Review, H2 2016

    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Pipeline Review, H2 2016

    • Report Code ID: RW0001499772
    • Category Pharmaceuticals
    • No. of Pages 36
    • Publication Month Nov-16
    • Publisher Name Global Markets Direct
    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Pipeline Review, H2 2016

    Summary

    Publisher's, 'Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Pipeline Review, H2 2016', provides in depth analysis on Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted pipeline therapeutics.

    The report provides comprehensive information on the Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics development and features dormant and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

    Note:
    *Certain sections in the report may be removed or altered based on the availability and relevance of data.
    *Updated report will be delivered in 48 hours of order confirmation.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)
    - The report reviews Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents

    List of Tables 4
    List of Figures 4
    Introduction 5
    Publisher Report Coverage 5
    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) Overview 6
    Therapeutics Development 7
    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Products under Development by Stage of Development 7
    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Products under Development by Therapy Area 8
    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Products under Development by Indication 9
    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Pipeline Products Glance 10
    Late Stage Products 10
    Early Stage Products 11
    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Products under Development by Companies 12
    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Products under Development by Universities/Institutes 14
    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Therapeutics Assessment 16
    Assessment by Monotherapy/Combination Products 16
    Assessment by Mechanism of Action 17
    Assessment by Route of Administration 18
    Assessment by Molecule Type 19
    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Companies Involved in Therapeutics Development 21
    Boehringer Ingelheim GmbH 21
    MedImmune LLC 22
    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Drug Profiles 23
    BI-836845 - Drug Profile 23
    Product Description 23
    Mechanism Of Action 23
    R&D Progress 23
    dusigitumab - Drug Profile 25
    Product Description 25
    Mechanism Of Action 25
    R&D Progress 25
    M-610.27 - Drug Profile 27
    Product Description 27
    Mechanism Of Action 27
    R&D Progress 27
    M-630 - Drug Profile 28
    Product Description 28
    Mechanism Of Action 28
    R&D Progress 28
    M-7085 - Drug Profile 29
    Product Description 29
    Mechanism Of Action 29
    R&D Progress 29
    Recombinant Protein to Inhibit IGF-1 and IGF-2 for Breast Cancer - Drug Profile 30
    Product Description 30
    Mechanism Of Action 30
    R&D Progress 30
    Recombinant Proteins to Inhibit IGF-2 for Oncology - Drug Profile 31
    Product Description 31
    Mechanism Of Action 31
    R&D Progress 31
    Small Molecules to Inhibit IGF-2 for Oncology - Drug Profile 32
    Product Description 32
    Mechanism Of Action 32
    R&D Progress 32
    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Dormant Projects 33
    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Featured News & Press Releases 34
    Jan 20, 2011: MedImmune Announces Positive Preclinical Results Of Anti-Cancer Drug 34
    Appendix 35
    Methodology 35
    Coverage 35
    Secondary Research 35
    Primary Research 35
    Expert Panel Validation 35
    Contact Us 35
    Disclaimer 36

    List of Tables

    Number of Products under Development for, H2 2016 7
    Number of Products under Development by Therapy Area, H2 2016 8
    Number of Products under Development by Indication, H2 2016 9
    Comparative Analysis by Late Stage Development, H2 2016 10
    Comparative Analysis by Early Stage Products, H2 2016 11
    Number of Products under Development by Companies, H2 2016 12
    Products under Development by Companies, H2 2016 13
    Number of Products under Investigation by Universities/Institutes, H2 2016 14
    Products under Investigation by Universities/Institutes, H2 2016 15
    Assessment by Monotherapy/Combination Products, H2 2016 16
    Number of Products by Stage and Mechanism of Action, H2 2016 17
    Number of Products by Stage and Route of Administration, H2 2016 18
    Number of Products by Stage and Molecule Type, H2 2016 20
    Pipeline by Boehringer Ingelheim GmbH, H2 2016 21
    Pipeline by MedImmune LLC, H2 2016 22
    Dormant Projects, H2 2016 33

    List of Figures

    Number of Products under Development for, H2 2016 7
    Number of Products under Development by Indication, H2 2016 9
    Comparative Analysis by Early Stage Products, H2 2016 11
    Assessment by Monotherapy/Combination Products, H2 2016 16
    Number of Products by Stage and Mechanism of Actions, H2 2016 17
    Number of Products by Stage and Routes of Administration, H2 2016 18
    Number of Products by Molecule Types, H2 2016 19
    Number of Products by Stage and Molecule Type, H2 2016 19
    Boehringer Ingelheim GmbH
    MedImmune LLC

    Request for Sample

    Report Url https://www.reportsweb.com//insulin-like-growth-factor-ii-pipeline-review-h2-2016&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//insulin-like-growth-factor-ii-pipeline-review-h2-2016&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//insulin-like-growth-factor-ii-pipeline-review-h2-2016&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments